US Patent

US9498465 — Topical compositions in the form of a gel containing a particular solubilized retinoid

Method of Use · Assigned to Galderma Research and Development SNC · Expires 2033-05-30 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of using a specific gel composition containing a particular solubilized retinoid, such as trifarotene, for cosmetic and dermatological purposes.

USPTO Abstract

A composition in the form of a gel, preferably hydroglycolic, is described. The composition can include in a physiologically acceptable medium, at least one particular retinoid. Also described, is a method for the preparation thereof and the cosmetic and dermatological use of the same.

Drugs covered by this patent

trifarotene (TRIFAROTENE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1033`	—	trifarotene

Patent Metadata

Patent number: US9498465
Jurisdiction: US
Classification: Method of Use
Expires: 2033-05-30
Drug substance claim: No
Drug product claim: Yes
Assignee: Galderma Research and Development SNC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.